- Trials with a EudraCT protocol (212)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
212 result(s) found for: Peak expiratory flow.
Displaying page 1 of 11.
EudraCT Number: 2011-001824-39 | Sponsor Protocol Number: CMID001A2201 | Start Date*: 2013-05-08 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A randomized, double-blind, double-dummy, placebo-controlled, 3-period crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol admi... | ||||||||||||||||||
Medical condition: Persistent Asthma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003066-32 | Sponsor Protocol Number: CQBX258X2201 | Start Date*: 2012-02-09 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized double-blind multiple-dose placebo-controlled trial to establish the efficacy of QBX258 (combination of VAK694 and QAX576) in asthma that is inadequately controlled with inhaled cortic... | |||||||||||||
Medical condition: Patients with asthma that are inadequately controlled with inhaled corticosteroids and long acting beta agonists | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001777-43 | Sponsor Protocol Number: 205.446 | Start Date*: 2012-05-15 | |||||||||||
Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily i... | |||||||||||||
Medical condition: Severe persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) LT (Completed) DE (Completed) BE (Completed) CZ (Completed) HU (Completed) PL (Completed) SK (Completed) RO (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004023-31 | Sponsor Protocol Number: LPS-Fluenz | Start Date*: 2016-01-06 |
Sponsor Name:Radboudumc | ||
Full Title: The effects of endotoxin challenge on the immune response elicited by a subsequent challenge with Fluenz™ in healthy volunteers, a pilot study | ||
Medical condition: Inflammatory conditions in general and immunosuppressive conditions is particular | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-004082-20 | Sponsor Protocol Number: T502-SIT-059 | Start Date*: 2023-03-07 | |||||||||||
Sponsor Name:Inmunotek S.L. | |||||||||||||
Full Title: An open phase III follow-up study in patients previously treated with mannan-conjugated birch pollen allergoids or placebo in the T502-045 trial. | |||||||||||||
Medical condition: Treatment of birch pollen-induced allergic rhinoconjunctivitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005469-12 | Sponsor Protocol Number: NEO-012 | Start Date*: 2006-01-06 |
Sponsor Name:Neolab Limited | ||
Full Title: A Phase III, randomised, double-blind, double-dummy cross-over study to compare two dry powder inhaled formulations of budesonide on methacholine hyper-reactivity in patients with stable, persisten... | ||
Medical condition: Stable, persistent, moderate asthma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-001758-26 | Sponsor Protocol Number: 205.445 | Start Date*: 2012-05-15 | |||||||||||
Sponsor Name:Boehringer | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily i... | |||||||||||||
Medical condition: Moderate persisten asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) LT (Completed) PT (Completed) DE (Completed) BG (Completed) SE (Completed) HU (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004892-61 | Sponsor Protocol Number: ADA109055 | Start Date*: 2016-12-21 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in ... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2005-005616-25 | Sponsor Protocol Number: 205.342 | Start Date*: 2006-07-31 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co.KG | |||||||||||||
Full Title: A 16-week randomised, placebo-controlled, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat® inhaler (2 ... | |||||||||||||
Medical condition: Patients with moderate persistent bronchial asthma and homozygous for arginine at the 16th position of the beta-2-adrenergic receptor | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) FI (Completed) BE (Completed) DK (Completed) IT (Completed) AT (Completed) GR (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001696-79 | Sponsor Protocol Number: KH176-201 | Start Date*: 2016-09-06 |
Sponsor Name:Khondrion BV | ||
Full Title: A double-blind, randomized, placebo-controlled, single-center, two-way cross-over study with KH176 in patients with the mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation and clinical signs of mitoc... | ||
Medical condition: Inherited mitochondrial disease, including MELAS (mitochondrial Encephalopathy Lactic Acidosis and Stroke like episodes) and MIDD (Maternally Inherited Diabetes and Deafness) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-004112-13 | Sponsor Protocol Number: 33100 | Start Date*: 2009-06-26 | |||||||||||
Sponsor Name:Nottingham University | |||||||||||||
Full Title: PPAR-gamma: A noval therapeutic target for asthma | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002523-17 | Sponsor Protocol Number: D589OC00003 | Start Date*: 2011-09-05 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A 12-week, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy, Safety, and Patient Use (User Study) of Symbicort® (Budesonide/Formoterol) Breath Actuated Metered D... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000520-18 | Sponsor Protocol Number: CQMF149E2203 | Start Date*: 2012-10-18 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo controlled, 12-week treatment, parallel-group study to assess the efficacy, safety and pharmacokinetics of indacaterol acetate (75 and 150 μg o.d.) ... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) SK (Completed) DE (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000644-17 | Sponsor Protocol Number: CQVM149B2209 | Start Date*: 2017-06-22 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, double-blind, repeat dose cross-over study to assess the bronchodilator effects of once daily QVM149 following morning or evening dosing for 14 days compared to placebo in patients wi... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004881-27 | Sponsor Protocol Number: SAS110101 | Start Date*: 2016-08-03 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: Clinical assessment of GW815SF Salmeterol/fluticasone propionate (HFA MDI) in pediatric patients with bronchial asthma -A long term (24-week) study- | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-004279-30 | Sponsor Protocol Number: SNT-III-012-E | Start Date*: 2018-06-14 | |||||||||||
Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited | |||||||||||||
Full Title: A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy (DMD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) GB (Prematurely Ended) FR (Ongoing) SE (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014551-80 | Sponsor Protocol Number: 1268.16 | Start Date*: 2010-01-21 | |||||||||||
Sponsor Name:BOEHRINGER ING. | |||||||||||||
Full Title: Randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 6 weeks of oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., or placeb... | |||||||||||||
Medical condition: patients with symptomatic asthma on inhaled corticosteroids | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) SE (Completed) DE (Completed) GB (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000642-35 | Sponsor Protocol Number: MK-1029-011-00 | Start Date*: 2012-10-25 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Crossover Study of MK-1029 in Adult Subjects with Persistent Asthma Who Remain Uncontrolled While Being Maintained on Montelukast | |||||||||||||
Medical condition: Adult subjects, 18 to 75 years of age, with persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003074-20 | Sponsor Protocol Number: MEN004 | Start Date*: 2005-08-17 | |||||||||||
Sponsor Name:University of Dundee | |||||||||||||
Full Title: Use Of Oral Montelukast As Adjuvant Therapy In The Treatment Of Acute Asthma | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003609-24 | Sponsor Protocol Number: CLOU064D12201 | Start Date*: 2019-10-09 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, subject- and investigator-blinded, placebo controlled study to assess the efficacy and safety of LOU064 in patients with inadequately controlled asthma | |||||||||||||
Medical condition: Inadequately controlled asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
